Cannabis Extract Market Size & Growth Forecast 2026–2035, By Segments (Product Type, Extract Type, Sources, End-use), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape

Market Size and Growth Outlook

Cannabis Extract Market size stood at USD 5.63 Billion in 2025 and is predicted to grow at a 19.8% CAGR from 2026 to 2035, reaching USD 34.28 Billion by 2035. The industry revenue for 2026 is calculated at USD 6.63 billion.

• Base Year Value (2025): USD 5.63 Billion
• CAGR (2026-2035): 19.8%
• Forecast Year Value (2035): USD 34.28 Billion
• Historical Data Period: 2022-2025
• Largest Region: North America
• Forecast Period: 2026-2035

Cannabis Extract Market Intelligence Snapshot:

• Regional Market Dynamics:

  • North America held a 75.36% market share in 2025, supported by mature licensed cultivation, standardized extraction, established retail channels, and strong medical and adult-use product demand.
  • Europe is projected to grow at a 22.18% CAGR, driven by expanding medical cannabis access, stronger physician acceptance, regulated supply development, and increasing demand for standardized extract formulations.

• Segment Momentum:

  • Oils accounted for 60.92% of the market in 2025 because they provide formulation flexibility, standardized dosing, and broad compatibility across medical, wellness, and consumer product applications.
  • Full Spectrum Extracts held a 67.87% share in 2025 while remaining the fastest-growing extract type due to strong demand for products retaining a broader range of plant compounds across multiple formulations.

• Market Expansion Drivers:

  • Expansion of medical cannabis legalization supporting therapeutic extract adoption.
  • Rising chronic disease burden increasing demand for cannabis-based therapies.
  • Product innovation in CBD oils and tinctures expanding pharmaceutical integration.

• Leading Market Participants:

  Key players in the cannabis extract market include Canopy Growth Corporation (Canada), Tilray Brands, Inc. (Canada), Aurora Cannabis Inc. (Canada), Cronos Group Inc. (Canada), Organigram Holdings Inc. (Canada), Tikun Olam Ltd. (Israel), Curaleaf Holdings, Inc. (United States), Green Thumb Industries Inc. (United States).

Unlock Complete Insights

Global Market Forecast Snapshot:

• Market Outlook:

  • 2025 Market Size: USD 5.63 Billion
  • 2026 Market Size: USD 15.2 billion
  • Projected Market Size: USD 34.28 Billion by 2035
  • Growth Forecasts: 19.8% CAGR (2026-2035)

• Regional and Segment Outlook:

  • Leading Regional Market: North America
  • High-Growth Regional Hub: Europe
  • Core Revenue Segment: Oils (Product Type) | Full Spectrum Extracts (Extract Type) | Marijuana (Sources) | Medical Use (End-use)
  • Emerging Opportunity Segment: Oils (Product Type) | Full Spectrum Extracts (Extract Type) | Marijuana (Sources) | Medical Use (End-use)

Market Growth Drivers and Industry Trends

Expansion of medical cannabis legalization supporting therapeutic extract adoption

As more jurisdictions formalize medical cannabis frameworks, the cannabis extract market benefits from a shift from informal consumption toward regulated, physician-guided therapeutic use. Legalization creates the conditions for licensed cultivation, standardized extraction, prescription pathways, and pharmacy or clinic-based distribution, which makes oils, tinctures, and other measured-dose formats more viable than smokable products in medical settings. This regulatory structure influences prescribing behavior and procurement decisions, aiding market expansion by giving healthcare providers and patients greater confidence in product consistency, cannabinoid content, and traceability.

Rising chronic disease burden increasing demand for cannabis-based therapies

The growing prevalence of chronic conditions such as persistent pain, neurological disorders, and treatment-resistant symptoms is reinforcing market demand for formulations that can be used over extended periods with dose control and administration flexibility. In the cannabis extract market, this favors extracts over raw flower because clinicians and patients often prefer products that fit repeatable therapeutic routines, especially when symptom management requires titration or combination cannabinoid profiles. Demand is shaped in practice by longer treatment journeys, ongoing symptom burden, and the search for adjunct therapies when conventional options deliver incomplete relief or create tolerability concerns.

Product innovation in CBD oils and tinctures expanding pharmaceutical integration

Advances in CBD oil and tincture formulation are supporting market development by making cannabis-derived products easier to align with pharmaceutical standards for dosing, stability, and patient usability. In the cannabis extract market, innovation is not limited to new product launches; it changes how manufacturers position extracts for clinical acceptance through improved bioavailability, more precise cannabinoid concentrations, and delivery formats suited to routine prescribing. That practical compatibility supports deeper integration into medical channels, where standardized non-inhalable products are more likely to gain attention from healthcare systems, formulary decision-makers, and companies pursuing regulated therapeutic applications.

Growth Driver Assessment Framework
Growth Driver	Impact On CAGR	Regulatory Influence	Geographic Relevance	Adoption Rate	Impact Timeline
Rising legalization and medical adoption of cannabis extracts	7.00%	Short term (≤ 2 yrs)	North America, Europe (spillover: Asia Pacific)	High	Fast
Expansion in recreational cannabis markets	6.00%	Medium term (2–5 yrs)	Europe, Asia Pacific (spillover: North America)	Medium	Moderate
Technological advancements in extraction and formulation	6.80%	Long term (5+ yrs)	North America, Europe (spillover: Asia Pacific)	Medium	Slow
Expansion of medical cannabis legalization supporting therapeutic extract adoption	2.70%	High	North America, Europe	High	Near Term
Rising chronic disease burden increasing demand for cannabis-based therapies	2.20%	High	North America, Middle East & Africa	High	Mid Term
Product innovation in CBD oils and tinctures expanding pharmaceutical integration	1.90%	Moderate	North America, Europe, Asia Pacific	Medium	Mid Term

Regional Demand Dynamics

North America (Largest Region) vs Europe (Fastest-Growing Region)

North America held a 75.36% share of the cannabis extract market in 2025, backed by a mature commercial framework in which licensed cultivation, extraction, product formulation, and retail channels are already functioning at scale. The region’s leadership is reinforced by established consumer demand across medical and adult-use applications, broader product availability, and the presence of experienced operators with the processing capacity to produce standardized extracts consistently. In practice, this allows manufacturers and distributors to move products more efficiently through regulated channels, supporting higher transaction volumes and deeper market penetration than in less-developed regional ecosystems.

Europe is projected to expand at a 22.18% CAGR over the forecast period, with growth in the cannabis extract market being propelled by the gradual widening of medical access and the steady buildout of regulated supply pathways. Momentum is being driven by increasing physician acceptance in applicable treatment settings, rising demand for standardized extract-based formulations, and stronger alignment around quality-controlled production and distribution. As regulatory pathways become more workable across parts of the region, market activity is accelerating through practical adoption patterns centered on prescribed use, import partnerships, and the expansion of compliant processing and dispensing infrastructure.

Regional Market Attractiveness & Strategic Fit Matrix
Parameter	North America	Asia Pacific	Europe	Latin America	MEA
Innovation Hub	Advanced	Developing	Advanced	Developing	Developing
Cost-Sensitive Region	Low	High	Medium	High	High
Regulatory Environment	Supportive	Restrictive	Supportive	Neutral	Neutral
Demand Drivers	Strong	Strong	Strong	Moderate	Moderate
Development Stage	Developed	Developing	Developed	Developing	Emerging
Adoption Rate	High	High	High	Medium	Medium
New Entrants / Startups	Dense	Moderate	Moderate	Sparse	Sparse
Macro Indicators	Strong	Strong	Stable	Stable	Stable

Key Country Insights

United States

Product Diversification Center

The U.S. cannabis extract market benefits from broad product innovation across medical and wellness applications. Companies in the U.S. are expanding extraction capabilities and developing differentiated formulations, including concentrates, tinctures, and ingredient-based consumer products.

Japan

Research-Oriented Development

Japan remains focused on research and regulatory assessment of cannabis-derived compounds rather than broad commercial adoption. Interest in Japan is centered on extracts with potential pharmaceutical applications and scientifically validated therapeutic properties.

South Korea

Controlled Therapeutic Access

South Korea maintains a tightly regulated environment where cannabis extracts are primarily considered for specific medical applications. Market activity in South Korea is concentrated on compliant import channels and carefully supervised therapeutic use cases.

Germany

Medical Cannabis Expansion

Germany's cannabis extract market is increasingly oriented toward pharmaceutical and therapeutic applications supported by evolving healthcare acceptance. German stakeholders are emphasizing standardized extracts and quality-controlled production suitable for prescription-based medical use.

France

Pharmaceutical Evaluation Pathway

France is assessing cannabis extracts through medical and clinical frameworks, encouraging interest in standardized formulations and patient access programs. The French market is prioritizing evidence-based applications and controlled distribution mechanisms for cannabis-derived products.

Italy

Specialty Extract Applications

Italy's cannabis extract market is supported by demand for medically oriented formulations and specialized therapeutic products. Companies in Italy are focusing on extraction quality, product consistency, and compliance with pharmaceutical-grade manufacturing requirements.

Segment Leadership and Growth Trends

  Product Type Segment Analysis: Oils (Largest & Fastest-Growing Segment)

Within the cannabis extract market, Oils accounted for a 60.92% share in 2025, reflecting both their established lead and continued expansion across end-use applications. This position is sustained by the practical versatility of oils, which fit easily into medical, wellness, and consumer product formats while offering dosing flexibility and straightforward formulation. Their ongoing growth momentum in the cannabis extract market is underpinned by the same operational advantages that drive current demand, especially as producers and buyers favor extract formats that are easier to standardize, blend, and integrate into a broad range of products than many alternative formats.

Extract Type Segment Analysis: Full Spectrum Extracts (Largest & Fastest-Growing Segment)

In 2025, Full Spectrum Extracts held a 67.87% share of the cannabis extract market, making them the dominant extract type while also maintaining the strongest growth momentum. Their leadership is grounded in sustained preference for extract profiles that preserve a wider range of plant compounds, aligning with market demand for products perceived as more complete and less heavily reduced than narrower extract alternatives. Growth in the cannabis extract market continues to favor Full Spectrum Extracts because this broader compound retention supports their use across diverse formulations, helping manufacturers meet evolving product expectations without shifting away from a format already widely accepted in the market.

Report Segmentation
Segment	Sub-Segment	Largest Segment	Fastest Growing Segment
Product Type	Oils, Tinctures	Oils	Oils
Extract Type	Full Spectrum Extracts, Cannabis Isolates	Full Spectrum Extracts	Full Spectrum Extracts
Sources	Hemp, Marijuana	Marijuana	Marijuana
End-use	Medical Use, Recreational Use	Medical Use	Medical Use

Competitive Landscape and Market Positioning

Top players in the cannabis extract market:

1. Canopy Growth Corporation (Canada)

2. Tilray Brands Inc. (Canada)

3. Aurora Cannabis Inc. (Canada)

4. Cronos Group Inc. (Canada)

5. Organigram Holdings Inc. (Canada)

6. Tikun Olam Ltd. (Israel)

7. Curaleaf Holdings Inc. (United States)

8. Green Thumb Industries Inc. (United States)

In the cannabis extract market, evolving regulatory frameworks are shaping product standardization and safety requirements. Innovation is focused on improving extraction purity and consistency. The cannabis extract market is also witnessing diversification in therapeutic and wellness applications. Research efforts are supporting improved formulation stability and efficacy.

Industry Development/News

Company Name	Date	Key Development
Artrix	Apr-26	Artrix introduced "Glassic," a specialized glass vape platform engineered for premium cannabis extracts. The hardware focuses on improving vapor purity and flavor profiles, providing manufacturers with a technical solution to enhance product performance and differentiation within the competitive cannabis extract-based vaping segment.
Somai Pharmaceuticals	Feb-26	Somai Pharmaceuticals is scaling its international footprint, currently operating in 12 countries with plans to expand to 18. This multi-market strategy strengthens the company’s distribution network for regulated cannabis extracts, leveraging regional regulatory approvals and partnerships to capture market share across European and other emerging international medical cannabis sectors.
Vertanical	Oct-25	Vertanical achieved Phase III clinical trial success for its VER-01 cannabis-derived therapy for chronic low back pain. This clinical milestone validates the company’s evidence-based therapeutic pipeline, significantly strengthening its regulatory standing in Europe and providing a foundation for upcoming pivotal clinical studies required for U.S. market entry.
Demecan	Jul-25	Demecan launched "FE 800 No.1," the first German-produced cannabis extract utilizing live rosin extraction technology. This innovation introduces premium extraction standards to the German medical cannabis market, signaling a shift toward higher-quality, fresh-processed products within the regulated supply chain and reinforcing the company’s competitive position in the region.
Grön	Mar-25	Grön expanded its portfolio with the launch of 1000mg high-dose infused chocolates across U.S. markets. This rollout reflects a strategic focus on large-format, value-oriented cannabis extract edibles, targeting high-frequency consumers and strengthening the company's competitive presence in the medical and recreational edible segments.
Raw Garden	Feb-25	Raw Garden introduced the "Sprout" vape platform, which utilizes terpene-safe materials to enhance extract purity and hardware sustainability. This development highlights a commitment to improving consumption technology and product integrity, reinforcing the company's position as a premium provider within the cannabis extract hardware ecosystem.
Tilray Medical	Mar-24	Tilray Medical secured regulatory approval in Portugal for its THC 5 / CBD 20 cannabis extract formulation. This authorization facilitates the commercialization of its pharmaceutical-grade products in the Portuguese medical market, strategically bolstering the company’s European cannabis portfolio and expanding its access to regulated medical patient populations.
Paul's Boutique	Jan-24	Paul’s Boutique implemented automation-driven manufacturing improvements to optimize the production of cannabis extracts. By focusing on operational modernization, the company aims to enhance batch consistency and overall process efficiency, setting a benchmark for quality standardization in the production of cannabis-based products.
Exka Inc	May-25	Health authorities issued a recall for Exka Inc.’s cannabis extract products in Quebec due to defective child-resistant packaging. This development underscores the stringent regulatory requirements governing cannabis distribution and highlights the operational risks manufacturers face regarding packaging compliance and supply chain safety within legal retail frameworks.
Cannazo India	Jul-24	Cannazo India leveraged national media exposure to showcase its medical cannabis extract innovations targeting multiple sclerosis patients. The initiative represents a strategic move to raise product visibility and commercialize therapeutic cannabis solutions within India's nascent medical cannabis sector, signaling potential for broader consumer acceptance of extract-based medical treatments.